Tetrasomy 21pter→q21.2 in a male infant without typical Down’s syndrome dysmorphic features but moderate mental retardation

I Rost, H Fiegler, C Fauth, P Carr, T Bettecken, J Kraus, C Meyer, A Enders, A Wirtz, T Meitinger, N P Carter, M R Speicher

Tetrasomy 21pter→q21.2 in a male infant without typical Down’s syndrome dysmorphic features but moderate mental retardation

Key points

- Genetic investigation of patients with a partial chromosome 21 imbalance should help define which genes of chromosome 21 play a key role in the various symptoms of Down’s syndrome.
- We present a male infant with an additional marker chromosome derived from chromosome 21. The patient’s phenotype was not characteristic of Down’s syndrome; however, he had moderate mental retardation, comparable to the cognitive defects usually seen in Down’s syndrome patients.
- Fine mapping of the involved region was achieved by array comparative genomic hybridisation on a recently developed 1 Mb large insert clone array.
- This approach allowed us to identify genes in the over-represented region. We used the recently established human chromosome 21 gene expression atlas in the mouse to correlate the expression pattern with the clinical phenotype.
- We found a compelling correlation between putative expression patterns and the phenotype of the patient. Many genes within the involved region are expressed during the development of the brain. Other genes that are Down’s syndrome candidate genes for heart defects, limb abnormalities, or gastrointestinal abnormalities were not present in this region.
- The specific region of chromosome 21 over-represented in this case appears to define genes contributing to mental retardation rather than to the other physical defects typical of Down’s syndrome.

Abbreviation: CGH, comparative genomic hybridisation
CASE REPORT
The patient is the second child of healthy, non-consanguineous parents, and was born after a normal pregnancy. At birth, the mother was 33 years old and the father was 40 years old. The birth weight was 3690 g (50th–75th centile), length 54 cm (75th–90th centile), and head circumference 34 cm (10th–25th centile). During the neonatal period, severe hypotonia was noted but no general lethargy. Referral at age of 27 months was mainly for speech retardation. His physical examination did not show clear physical signs associated with Down’s syndrome (fig 1). Both length (85 cm) and weight (11 kg) lay between the 3rd and 10th centile, and the head circumference (47 cm) was below the 3rd centile. The face was round without brachycephaly (fig 1A, B). The palpebral fissures were slightly upslanting. The iris showed patterns resembling Brushfield spots. The ears were of normal size and the mouth was frequently open. The fifth finger appeared to be somewhat shortened (fig 1C). The gap between the first and second toes was slightly increased but not to the extent usually seen in patients with Down’s syndrome (fig 1D). The dermatoglyphic features revealed ulnar loops on all fingertips, but no transverse palmar crease. A congenital heart defect was ruled out by an electrocardiogram and ultrasound.

A thorough neurological examination was performed, which revealed developmental retardation in the range of 10–12 months. The developmental quotient, based on the Bayley Scales of Infant Development, was determined to be below 50. The Jackson score for the patient was 5, which is borderline between normal and patients with Down’s syndrome. The Rex/Preuss score was –2.49, thus within the normal range.

In summary, the patient had no definite dysmorphic features; however, he did display a significant developmental delay consistent with the diagnosis of moderate mental retardation (summary in table 1).

METHODS

GTG banding analysis
Metaphase preparation was performed according to standard protocols.

FISH to determine the chromosomal origin
The labelling and hybridisation of painting probes was performed according to standard protocols as described previously.13

Pools of human ribosomal DNA 11.9 kb and 19.8 kb EcoRI fragments14 were used for the delineation of rDNA. Probe preparation, labelling, and hybridisation were as described previously.15 16

Array CGH
Array CGH was performed on the recently developed human 1 Mb large insert clone array.12 This array consists of about 3 500 clones selected from the published Golden Path, which are spaced at approximately 1 Mb intervals across the genome. Hybridisation and array evaluation were performed according to previously published protocols.17

Confirmation with BAC hybridisations
We selected six BAC clones to confirm the array CGH results. The map positions of the clones are depicted in fig 2, these clones were: RP11-126N20 (fig 2, no. 2), RP1-270M7 (no. 3), RP1-152M24 (no. 4), RP11-132H24 (no. 13), AP000233 (RP4-655M9) (no. 14), and RP11-266G18 (no. 15). Labelling and hybridisation was performed according to previously published protocols.17

Parental origin of the marker chromosome
Two pairs of primers were selected for microsatellite markers (D21S1256 and D21S1914) from the ABI Prism Linkage Mapping Set-MD 10 (Applied Biosystems). The primers lay within the tetrasomic chromosome content of the marker chromosome.

Using PCR, 1 μg DNA (100–200 μg/ml) from mother, father, and child was amplified using the aforementioned fluorochrome labelled primer pairs. Conditions of amplification were as specified by the manufacturer except that the reaction volume was 25 μl and the number of cycles was reduced to 30, A 1 μl aliquot of the PCR product was diluted to 12 μl in HiDi Formamide (Applied Biosystems), denatured at 94°C for 3 minutes, chilled on ice, and analysed on an ABI 3100 capillary sequencer (Applied Biosystems) in the Genescan mode using procedures as specified by the manufacturer. Evaluation of runs was performed with the Genescan Software (version 2.0; Applied Biosystems).

RESULTS AND DISCUSSION

Banding analysis and FISH to determine the chromosomal origin
The GTG banding analysis revealed an extra marker chromosome, which was bisatellited, in all analysed cells of the patient. Its morphology suggested a derivation from a G group chromosome. The chromosomes of both parents were normal (data not shown).

Two colour experiments with a chromosome 21 painting probe and a rDNA probe demonstrated that the marker was derived from chromosome 21 (fig 3). The marker showed rDNA signals on both ends of the chromosome. Together with the GTG and DAPI banding patterns, it was concluded that this bisatellitised dicentric marker could best be described as a psu dic(21).

Fine mapping of the marker chromosome breakpoint using array CGH and BAC hybridisations
With the exception of chromosome 21, array CGH revealed balanced ratio profiles for all other chromosomes (data not shown). The array CGH results for chromosome 21 are illustrated in fig 2. The proximal chromosome 21 clones had log2 ratio values of 1, which corresponds to four copies or a tetrasomy for the respective region. Of special interest was clone RP11-266G18 (no. 15 in fig 2) which showed a log2 ratio value of 0.3 increase above BAC clones with balanced ratio values (log2 of 0) but lower than the other BAC clones within the tetrasomic region.

For several clones (2–4 and 13–15) we corroborated the array ratio values with BAC clone hybridisations. With the exception of clone RP11-266G18, hybridisation of all other clones resulted in two signals on the marker chromosome. The distance between these two signals was larger for clones close to the centromere and became narrower as more distal clones were mapped. Clone RP11-266G18 was believed to be breakpoint spanning because its ratio value yielded only one signal on the marker chromosome. This signal was smaller than the signals observed on the two normal chromosomes 21 (fig 2). Thus the breakpoint is within clone 15, within chromosome band 21q21.2.

The long arm of chromosome 21 has a length of 33.5 Mb and carries 225 genes.18 Our fine mapping of the breakpoint revealed that the marker chromosome includes the proximal 12.4 Mb or 37.0% of the long arm. This region harbours 34 (15.1%) of the 225 genes on chromosome 21.

Parental origin of the marker chromosome
The parental origin of the marker chromosome was determined using several markers (D21S1914, D21S1256). This
Table 1  Cytogenetic and clinical features of cases with complete and partial tetrasomy 21

<table>
<thead>
<tr>
<th>Case report</th>
<th>Ref. 4</th>
<th>Ref. 5</th>
<th>Ref. 6</th>
<th>Ref. 7</th>
<th>Ref. 8</th>
<th>This case</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral lymphocytes</td>
<td>48,XY,+21,+21</td>
<td>47,XX, idic(21)(q22.11)</td>
<td>47,XY,+psu dic(21)(q22.1)</td>
<td>47,XY,+psu dic(21)(q22.11)</td>
<td>47,XY,+psu idic(21)(q22.11)</td>
<td>47,XY,+psu idic(21)(q22.11)</td>
</tr>
<tr>
<td>Parental chromosomes</td>
<td>Normal</td>
<td>Maternal studies Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Mother’s age</td>
<td>24 years</td>
<td>32 years</td>
<td>33 years</td>
<td>46 years</td>
<td>34 years</td>
<td>33 years</td>
</tr>
<tr>
<td>Father’s age</td>
<td>36 years</td>
<td>NI</td>
<td>32 years</td>
<td>52 years</td>
<td>33 years</td>
<td>40 years</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Spitting/cough</td>
<td>Normal</td>
<td>Bleeding</td>
<td>NI</td>
<td>j weight gain</td>
<td>Normal</td>
</tr>
<tr>
<td>Gestation</td>
<td>32 weeks</td>
<td>Term</td>
<td>38 weeks</td>
<td>NI</td>
<td>33 weeks</td>
<td>Term (39 weeks)</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>2020</td>
<td>2940</td>
<td>3600</td>
<td>3300</td>
<td>1420</td>
<td>3690 g</td>
</tr>
<tr>
<td>Age at referral</td>
<td>4 days</td>
<td>33 months</td>
<td>29 months</td>
<td>9.2 years</td>
<td>18 months</td>
<td>27 months</td>
</tr>
<tr>
<td>Length</td>
<td>89.5 cm (25th)</td>
<td>90 cm (50th)</td>
<td>NL range</td>
<td>68 cm (&lt;3rd)</td>
<td>85 cm (3rd-10th)</td>
<td></td>
</tr>
<tr>
<td>Weight</td>
<td>12.0 kg (10th)</td>
<td>10.9 kg (10th)</td>
<td>NL range</td>
<td>8.88 kg (&lt;3rd)</td>
<td>11 kg (3rd-10th)</td>
<td></td>
</tr>
<tr>
<td>Head circumference</td>
<td>45.5 cm (&lt;3rd)</td>
<td>45.5 cm (1&lt;3rd)</td>
<td>NL range</td>
<td>40.3 cm (&lt;3rd)</td>
<td>47 cm (&lt;3rd)</td>
<td></td>
</tr>
<tr>
<td>Motor development</td>
<td>NI</td>
<td>Normal</td>
<td>Unable to walk</td>
<td>Retarded</td>
<td>Unable to sit</td>
<td>Retarded</td>
</tr>
<tr>
<td>Speech</td>
<td>NI</td>
<td>Single words</td>
<td>I</td>
<td>Babble</td>
<td>Single words</td>
<td></td>
</tr>
<tr>
<td>Jackson Score</td>
<td>9</td>
<td>10</td>
<td>7</td>
<td>1</td>
<td>12</td>
<td>5</td>
</tr>
<tr>
<td>Brachycephaly</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Upplanted palpebral fissures</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Epicanthal folds</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Brushfield spots</td>
<td>NI</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Flat nasal bridge</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>++</td>
</tr>
<tr>
<td>Open mouth</td>
<td>NI</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Protruding tongue</td>
<td>NI</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Furrowed tongue</td>
<td>NI</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Ears small/low set</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Short neck</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Excess nuchal skin</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Short and broad hands</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Short fifth finger</td>
<td>NI</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>(+)</td>
</tr>
<tr>
<td>Transverse palmar crease</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Gap between 1st and 2nd toes</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>(+)</td>
</tr>
<tr>
<td>Congenital heart defect</td>
<td>PDA</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Muscular hypotonia</td>
<td>+</td>
<td>+</td>
<td>NI</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

NI, no information; NI, normal; +, symptom present; (+), symptom present with less characteristic features; –, symptom absent.
analysis indicated that the extra chromosome was of maternal origin and not identical with the maternal chromosome 21, which was inherited in toto (data not shown).

Genes within the tetrasomic region and their potential contribution to specific symptoms of Down's syndrome

Genes within the tetrasomic region were identified using the Ensembl Human Genome Browser (www.ensembl.org; release version 14.13.1; accessed 2 June 2003), which lists all known and novel genes predicted by Ensembl. The 34 genes in the over-represented chromosome 21 region are listed in table 2. Twenty of these 34 genes are designated as "novel" and no specific function has as yet been assigned to these genes.

The exact effect of the over-representation of the other, "known" genes is difficult to estimate as genes may be active only in some tissues and only at specific stages of embryonic development. In order to check how these genes may have contributed to the patient's phenotype, we used the recently established human chromosome 21 gene expression atlas in the mouse.10 11 This atlas indicates when and where murine orthologues of human chromosome 21 genes are expressed during development.

The atlas indicated five mouse orthologous genes (SAMSN1, USP25, CXADR, C21orf91/YG-81, and CHODL) with a high expression in the brain, and five genes (TPTE/PTEN2, STCH, NRIP1/RIP140, BTG3, and NCAM2) with a clear identification of the transcript in the brain. All of these genes were within the over-represented chromosome 21 region and may contribute to the cognitive defects of the patient and similarly

Figure 2  Summary of the array CGH and FISH fine mapping results. The top of the figure shows a diagram of chromosome 21. The segment, which is shown enlarged at the bottom, is encircled in red. The array CGH results are indicated in a coordinate system. The abscissa shows the position of the clones in Mb according to the draft genomic sequence and the ordinate the mean log2 ratios of the duplicated spots normalised to the median log2 ratio for the genome as described.12 For the ratios, 0 = a balanced ratio, 0.5 = a trisomy, and 1 = a tetrasomy. Below the coordinate system is the exact map position of chromosome 21 BAC clones shown (the representation was taken from the Ensembl server release 14.31.1 from June 2, 2003). The top two rows display BAC clones from the 1 Mb clone set. These are the clones, which are present on the array. The third row displays some probes from the tiling path. The most proximal clones were numbered from 1 to 16 as follows: (1) RP11-193b6, (2) RP11-126H20, (3) RP1-270M7, (4) RP1-152M24, (5) RP11-43A6, (6) RP11-304D2, (7) RP11-49B5, (8) RP11-50A12, (9) RP11-509A5, (10) RP11-258A5, (11) RP11-25F24, (12) RP11-15H23, (13) RP11-132H24, (14) AP000233/RP4-65SM9, (15) RP11-266G18, and (16) RP11-15H6. Illustrated below the probes is the location of the genes. Known Ensembl predicted genes are shown in red, novel Ensembl predicted genes are shown in black. Displayed at the bottom of the figure are FISH images of BAC clones 2–4 and 13–15. In all cases, the two normal chromosomes 21 are shown to the left, the right chromosome is the idic(21q). The proximal chromosome 21 BAC clones in the map are connected to their respective ratio values in the coordinate system or to their respective FISH images.

Table 2  Genes within the tetrasomic region of chromosome 21

<table>
<thead>
<tr>
<th>Chromosome band</th>
<th>Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>p11.2</td>
<td>TPTE/PTEN2, Novel (12x)</td>
</tr>
<tr>
<td>q11.2</td>
<td>ABC13, SAMSN1, STCH, NRIP1/RIP140, Novel (7x)</td>
</tr>
<tr>
<td>q21.1</td>
<td>USP25, CXADR, BTG3, C21orf91/YG-81, CHODL, Novel (1x)</td>
</tr>
<tr>
<td>q21.2 proximal to breakpoint</td>
<td>C21orf68/PRED12, PRK57, PPSA, NCAM2</td>
</tr>
</tbody>
</table>

Based on the data in the Ensembl server, these genes were selected. Thirty-four genes are within the tetraploid region. Genes included in the human chromosome 21 gene expression atlas10 are in bold.
interact with others in the tetrasomic region and are thus the same time, we cannot rule out the possibility that these genes defects in our patient can be attributed to these genes. At the somal region. It is therefore unlikely that the cognitive 

**Figure 3** Metaphase spread after hybridisation with a chromosome 21 painting probe (green) and a rDNA probe (red). The chromosome 21 painting probe hybridised to both chromosomes 21 and to the marker chromosome. The rDNA probe results in a red staining of the p arms of all acrocentric chromosomes. Note that there are red signals at either end of the marker chromosome (the overlap of green and red fluorescence results in one yellow signal), indicating that the marker is a dicentric chromosome.

to the cognitive defects in Down’s syndrome. In contrast, other genes that have been discussed as potential candidates for the cognitive defects of Down’s syndrome, such as DSCAM, SYNJ1, PTGGLIP, WRB, COL18A1, COL6A1, and COL6A2, were not within the over-represented chromosomal region. It is therefore unlikely that the cognitive defects in our patient can be attributed to these genes. At the same time, we cannot rule out the possibility that these genes interact with others in the tetrasomic region and are thus indirectly affected.

Our patient may help to narrow down the roles of other genes contributing to Down’s syndrome. Trisomy 21, for example, is also associated with specific heart abnormalities at the atrioventricular canal and atrial septum. Candidate genes for these heart defects, according to the chromosome 21 expression atlas, are PWP2H, C21ORF14, PEKL, ADARB1, C21ORF18, KCN15, SH3BGR, and KCNE2. None of these genes lies within the tetrasomic region and our patient had no heart anomalies.

The gene expression atlas identified genes such as ATP5O, CLDN8, CLIC6, ETS2, TFF3, HMGN1, SH3BGR, WRB, and SOD1 as candidates that may be potentially responsible for gastrointestinal abnormalities, which are observed in some Down’s syndrome patients. None of these genes is located in the over-represented region identified here, which may therefore explain the lack of any gastrointestinal symptoms in this patient.

Other genes, including TIAM1, SNF1LK, ERG, and ADAMTS1, are associated with abnormalities of the extremities, such as reduced growth of long limb bones or the hypoplastic middle phalanx of the fifth digit. In our patient, these abnormalities were not observed and none of these genes lies within the tetrasomic chromosome 21 region.

In summary, this case allows a correlation of human chromosome 21 expression patterns with specific phenotypic features and may add to previous reports of genes contributing to mental or physical defects typical of Down’s syndrome (reviewed in Roizen & Patterson). In addition, published phenotypes associated with tetrasomy 21 material have described some physical features uncommon in trisomy 21. These phenotypic effects have been attributed to the four copies of chromosome 21 material. This tetrasomy is likely to be more severe than trisomy of the same chromosome segment because of a correspondingly greater imbalance in gene dosage. Similar dosage effects were reported for other tetrasomies, such as 12p or 15q. In our patient, the greater gene dosage imbalance had no obvious effect on any dysmorphic features, which makes it unlikely that the over-represented genes are involved in any of dysmorphic features typically attributed to Down’s syndrome. We propose that the genes in this proximal region may contribute to the moderate mental retardation and the cognitive defects of Down’s syndrome.

**ACKNOWLEDGEMENTS**

We are grateful to the patient’s family for their support and collaboration. This work was supported by the Deutsche Forschungsgemeinschaft (Sp 4604–1) and the Bundesministerium für Bildung und Forschung (NGFN KB P06F5, P06Y6).

**Authors’ affiliations**

I Rost, A Wirtz, Abteilung für Medizinische Genetik der Kinderklinik, Ludwig Maximilians Universität München, Goethestr. 29, D-80336 München, Germany

H Fiegler, P Carr, N P Carter, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK

C Fauth, T Bettecken, J Kraus, C Meyer, T Meitinger, M R Speicher, Institut für Humangenetik, Technische Universität München, Trogerstr. 32, D-81675 München, Germany, and GSF-Forschungszentrum für Umwelt und Gesundheit, D-85764 Neuherberg, Germany

Angelika Enders, Zentrum für Entwicklungsneurowissenschaft und Frühförderung im Dr. von Haunerschen Kinderspital, Ludwig Maximilians Universität München, Lindwurmstr. 4, D-80337 München, Germany

Christine Fauth, Universität Innsbruck, Institut für Med. Biologie und Humangenetik, Schoeppflstr. 41, A-6020 Innsbruck, Austria

Correspondence to: Dr M R Speicher, Institut für Humangenetik, TU München, Trogerstr. 32, D-81675 München, Germany; speicher@humangenetik.med.tu-muenchen.de

Received 2 September 2003 Accepted 22 September 2003

**REFERENCES**


Tetrasomy 21pter→q21.2 in a male infant without typical Down's syndrome dysmorphic features but moderate mental retardation

I Rost, H Fiegler, C Fauth, P Carr, T Bettecken, J Kraus, C Meyer, A Enders, A Wirtz, T Meitinger, N P Carter and M R Speicher

J Med Genet 2004 41: e26
doi: 10.1136/jmg.2003.011833

Updated information and services can be found at:
http://jmg.bmj.com/content/41/3/e26

These include:
References
This article cites 18 articles, 4 of which you can access for free at:
http://jmg.bmj.com/content/41/3/e26#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Congenital heart disease (82)
Memory disorders (psychiatry) (67)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/